Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00346684
Status:
COMPLETED
Last Update Posted:
2008-08-12
First Post:
2006-06-29
Brief Title:
Rituximab in Primary Lymphocyte Predominant Hodgkins DiseaseRIPL
Sponsor:
University of Cologne
Organization:
University of Cologne
Study Overview
Official Title:
Rituximab in Primary LPHD RIPL - First Line Therapy for Patients With Lymphocyte Predominant Hodgkins Disease LPHD in Clinical Stage IA Using the Monoclonal Anti-CD20 Antibody Rituximab
Status:
COMPLETED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
First line therapy for patients with Lymphocyte predominant Hodgkins Disease LPHD in clinical stage IA using the monoclonal anti-CD20 antibody rituximab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None